A recent study suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a prominent medical journal shows that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People using these drugs must be cognizant of the risk of fast weight regain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about 18 months.
Analyzing Therapies
The research, which reviewed 37 of trials involving thousands of participants, contrasted the effects of these new drugs with other pills.
The team emphasize that individuals who lose weight through dieting generally experience a slower creep back—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors propose the mechanism of the injections is key to understanding the accelerated rebound.
The injections copy a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of relapse, the treatment might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "highlight the persistent nature of obesity," akin to managing diseases like diabetes.
Patient Experiences
People who have discontinued the medication report a sudden return of hunger.
"It was like a switch that goes on and I was suddenly starving," recalled an individual.
This challenge is compounded if patients have not developed lasting dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while these medications are potent tools for weight loss, they are not a standalone solution and maintained weight loss relies on combined lifestyle changes.
